Orthogonal validation of PROTAC mediated degradation of the integral membrane proteins EGFR and c-MET
Abstract Dysregulation of integral membrane proteins (IMPs) has been linked to a myriad of diseases, making these proteins an attractive target in drug research. Whilst PROTAC technology has had a significant impact in scientific research, its application to IMPs is still limited. Limitations of the...
Saved in:
Main Authors: | Camilla Ruffilli, Sascha Röth, Noam Zelcer, Kevin Moreau |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-024-84217-2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PROTACs: Mechanism and Bioavailability enhancement strategies by nanotechnology, RNA viral infections (vaccine strategy) and Prodrug development
by: Sanaul Mustafa, et al.
Published: (2025-01-01) -
A Case Report of EGFR-TKIs Resistant Secondary MET Gene Amplified
Lung Squamous Cell Carcinoma and Literature Review
by: Yalan LIU, et al.
Published: (2024-11-01) -
Potential application of proteolysis targeting chimera (PROTAC) modification technology in natural products for their targeted protein degradation
by: Guliang Yang, et al.
Published: (2022-03-01) -
PROTAC-based therapeutics for targeting HPV oncoproteins in head and neck cancers
by: Nobendu Mukerjee, et al.
Published: (2025-12-01) -
A pH-responsive PROTAC-based nanosystem triggers tumor-specific ferroptosis to construct in situ tumor vaccines
by: Linghong Huang, et al.
Published: (2025-04-01)